Xiaoyun Huang

Dr. Xiaoyun Huang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2020 in Genes & Diseases
Verified
Journal Article
Open access
SWShuhang Wang
Shuhang Wang
MJMiaomiao Jiang
Miaomiao Jiang
ZYZuozhen Yang
Zuozhen Yang
XHXiaoyun Huang
Xiaoyun Huang
NLNing Li
Ning Li
TP53 mutations was reported to be correlated to the efficacy of program death-1 (PD-1) and program death ligand-1 (PD-L1). The role of co-mutations of TP53 with other recurrently mutated genes in outcome of anti-PD-(L)1 treatment for non-small cell lung cancer (NSCLC) is unknown. Here we mined a previously generated dataset to address the effect of co-mutations on the progression free survival (PFS) of NSCLC patients. Non-synonymous mutations and clinical data of 240 NSCLC patients with anti-PD-(L)1 based therapy was downloaded from cBioPortal. Totally 206 patients received monotherapy and 34 patients received combination therapy. In 240 NSCLC patients, TP53 mutation rate was 59.2%. For the monotherapy cohort, TP53 mutated NSCLC patients have a significantly longer PFS (4.3 vs. 2.5 months, P = 0.0019) compared with TP53 wild type NSCLC patients. The same tendency was also observed in the combination therapy cohort, but the difference in PFS (6.3 vs. 5.4 months, P = 0.12) was not significant. Ever-smoker had a longer PFS compared to never-smokers (4.0 vs. 2.7 months). For further co-mutation analysis with TP53 including KEAP1 mutation (53/240, 22.1%), KMT3C mutation (26/240, 10.8%), STK11 mutation (56/240, 23.3%), EGFR mutation (28/240, 11.7%) and KRAS mutation (86/240, 35.8%). Patients with both TP53 plus KEAP1 mutations in all 240 patients had a longer PFS compared with co-wild population (PFS 9.2 vs. 4.2 months, P = 0.012) when treated with PD-1/PD-L1 inhibitors. TP53 might be the dominating mutation correlating with longer PFS in PD-1/PD-L1 monotherapy. Different genes displayed distinct effect when co-mutated with TP53 in NSCLC patients.

13 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
YZYanyan Zhu
Yanyan Zhu
BCBowang Chen
Bowang Chen
JYJunya Yan
Junya Yan
WZWendi Zhao
Wendi Zhao
PDPengli Dou
Pengli Dou
XHXiaoyun Huang
Xiaoyun Huang
BNIP3 is a BH3-only protein with both pro-apoptotic and pro-survival roles depending on the cellular context. It remains unclear how BNIP3 RNA level dictates cell fate decisions of cancer cells. Here, we undertook a quantitative analysis of BNIP3 expression and functions in single-cell datasets of various epithelial malignancies. Our results demonstrated that BNIP3 upregulation characterizes cancer cell subpopulations with increased fitness and proliferation. We further validated the upregulation of BNIP3 in liver cancer 3D organoid cultures compared with 2D culture. Taken together, the combination of in silico perturbations using public single-cell datasets and experimental cancer modeling using organoids ushered in a new approach to address cancer heterogeneity.

4 January 2024 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
JYJianwei Yu
Jianwei Yu
YJYan Jia
Yan Jia
QYQichao Yu
Qichao Yu
LLLan Lin
Lan Lin
CLChao Li
Chao Li
YPYuanming Pan
Yuanming Pan
Introduction: Helicobacter pylori (H.pylori, Hp) affects billions of people worldwide. However, the emerging resistance of Hp to antibiotics challenges the effectiveness of current treatments. Investigating the genotype-phenotype connection for Hp using next-generation sequencing could enhance our understanding of this resistance.Methods: In this study, we analyzed 52 Hp strains collected from various hospitals. The susceptibility of these strains to five antibiotics was assessed using the agar dilution assay. Whole-genome sequencing was then performed to screen the antimicrobial resistance (AMR) genotypes of these Hp strains. To model the relationship between drug resistance and genotype, we employed univariate statistical tests, unsupervised machine learning, and supervised machine learning techniques, including the development of support vector machine models.Results: Our models for predicting Amoxicillin resistance demonstrated 66% sensitivity and 100% specificity, while those for Clarithromycin resistance showed 100% sensitivity and 100% specificity. These results outperformed the known resistance sites for Amoxicillin (A1834G) and Clarithromycin (A2147), which had sensitivities of 22.2% and 87%, and specificities of 100% and 96%, respectively.Discussion: Our study demonstrates that predictive modeling using supervised learning algorithms with feature selection can yield diagnostic models with higher predictive power compared to models relying on single single-nucleotide polymorphism (SNP) sites. This approach significantly contributes to enhancing the precision and effectiveness of antibiotic treatment strategies for Hp infections. The application of whole-genome sequencing for Hp presents a promising pathway for advancing personalized medicine in this context.

11 April 2025 in Med
Verified
Journal Article
Closed access
XHXiaoyun Huang
Xiaoyun Huang
LGLei Gu
Lei Gu
JSJian Sun
Jian Sun
RERoland Eils
Roland Eils

4 December 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YZYanyan zhu
Yanyan zhu
SCShundong Cang
Shundong Cang
BCBowang Chen
Bowang Chen
YGYue Gu
Yue Gu
MJMiaomiao Jiang
Miaomiao Jiang
XHXiaoyun Huang
Xiaoyun Huang
Clear cell renal cell carcinoma represents the most common type of kidney cancer. Precision medicine approach to ccRCC requires an accurate stratification of patients that can predict prognosis and guide therapeutic decision. Transcription factors are implicated in the initiation and progression of human carcinogenesis. However, no comprehensive analysis of transcription factor activity has been proposed so far to realize patient stratification. Here we propose a novel approach to determine the subtypes of ccRCC patients based on global transcription factor activity landscape. Using the TCGA cohort dataset, we identified different subtypes that have distinct up-regulated biomarkers and altered biological pathways. More important, this subtype information can be used to predict the overall survival of ccRCC patients. Our results suggest that transcription factor activity can be harnessed to perform patient stratification.

15 December 2020 in Occupational and Environmental Medicine
Verified
Journal Article
Closed access
PDF file
YFYali Fan
Yali Fan
CZChunming Zheng
Chunming Zheng
NWNa Wu
Na Wu
YLYihua Li
Yihua Li
XHXiaoyun Huang
Xiaoyun Huang
QYQiao Ye
Qiao Ye
Objectives: Telomerase gene variants that lead to accelerated telomere shortening are linked to progressive-fibrosing interstitial lung diseases. However, little is known about their relationships with pneumoconiosis. This study aimed to identifyTERT/TERCvariants and leucocyte telomere lengths (LTL) in patients with silicosis or asbestosis.Methods: In the present study, Sanger sequencing ofTERT/TERCvariants was performed in 193 Chinese Han patients with pneumoconiosis, including 109 with silicosis and 84 with asbestosis. Quantitative PCR was used to measure LTL in peripheral blood of the patients and 200 age and sex-matched healthy controls.Results: In total, 7.3% patients with pneumoconiosis had 17TERT/TERCvariants. Among which 8.3% of patients with silicosis and 3.6% of patients with asbestosis hadTERTvariants, respectively. NoTERCvariants were detected in silicosis, whereas 3.6% of patients with asbestosis hadTERCvariants. Telomeres were significantly shorter in the patients with pneumoconiosis compared with healthy controls (p<0.001). No significant differences in LTL were found betweenTERT/TERCvariant carriers and non-carriers. Exposure to silica dust was associated with the severity of pneumoconiosis after adjusting for covariates (OR 4.92, p=0.002). However,TERT/TERCvariants and short telomeres were not associated with the severity of pneumoconiosis.Conclusion: Telomerase gene variants and short telomeres may be identified in the patients with silicosis and asbestosis in response to the exposure to silica or asbestos dust but are not related to disease severity.